Objectives: To use structured deliberation to elicit and describe the values of the public in Alberta, Canada, on the question of whether the severity of a rare condition can justify it being given priority in funding over common conditions affecting larger numbers of patients, and what aspects of a condition drive this judgment. Methods: Thematic analysis of transcripts of a group deliberative exercise carried out as part of two citizens' juries. The exercise was designed to elicit participants' conception of disease severity, and trade-offs between helping small groups with severe conditions and larger groups with less severe conditions. Results: In trading off severity and numbers, all groups were willing to choose a more severely ill but smaller group of patients over a less severely ill but larger group of patients, although how much of a severity differential was required varied between groups. Pain that could not be relieved by alternative means was the strongest motivator for choosing the smaller group. Other symptoms with no alternative means of relief were strong motivators as well. Conclusions: These findings indicate that, all else being equal, the public would support giving priority to a smaller but more severely ill group of patients over a larger group when prioritizing the needs of the few is life-saving, extends life enough to give hope of future improvement, and relieves otherwise intractable symptoms, especially pain.
Introduction
Rare diseases are usually genetic, often chronic and severe. Their rarity limits the potential size of the market for treatments. As a result, absent special incentives, anticipated returns on investment may be insufficient to stimulate development of treatments, and those that reach the market may have very high prices. To counteract these tendencies, many countries have successfully adopted policies to stimulate development of treatments for rare diseases, help these treatments reach the market, and promote access to them [1, 2] . In the absence of such a policy, by 2012, 74% of the orphan drugs approved in the United States were available in the Canadian market. Canadian approvals often happened later [3] , and provinces adopted informal mechanisms for providing access to these drugs [4] . In October 2012, the federal government started to develop an orphan drug regulatory framework.
Because drugs for rare diseases are rarely considered costeffective by usual criteria [5] , decisions to cover these drugs require departing from usual cost-effectiveness requirements, treating these diseases as priority cases for which society is willing to pay more than it would pay to treat common diseases. Studies find that the public is unwilling to pay more for the same health gains because of a disease's rarity [6] [7] [8] , but supports prioritizing the more severely ill, to some extent: a person trade-off study in Norway finds no preference for severity, all else being equal [8] . A person trade-off study in the United States [9] finds preference for severity even at the expense of some aggregate gain, whereas one in the United Kingdom [10] finds no preference for rarity but preference for severity only if health gain is substantial. A deliberative study in the United Kingdom finds that the "rule of rescue" was one of three rationing principles chosen by deliberators [11] . Reviews of preference studies find a consistent preference for severity, although its strength varies [12, 13] . A review of social value arguments also finds support for valuing severity but not rarity [14] .
Orphan drugs treat diseases that are not only rare, but also severe. Because there is no preference for rarity but there is preference for severity, it becomes necessary to investigate whether severity can outweigh smaller numbers in public preferences for funding allocation, and, if so, what aspects of severity can do so. The exercise described here aims to elicit considered judgments from citizens of Alberta regarding this question, as well as the rationales for these judgments.
Methods
Citizens' juries are a method for engaging the public in structured deliberation. Deliberation allows citizens to articulate and justify their views in terms that should be acceptable to others, to be exposed to the views of others, and to broaden and revise their own views [15] . Research on the effects of citizens' juries shows that participation increases jurors' openness to changing their views, influences jurors' opinions, and has long-term effects on their level of information about the policy issue in question and positive effects on trust in health technology assessment processes [16] [17] [18] [19] .
Two citizens' juries were involved in this study. Each consisted of 16 members of the public who were compensated for their time to make participation accessible for all socioeconomic strata. To minimize selection bias due to inability to get time off of work, juries were held on a Friday evening, Saturday, and Sunday. The first jury took place from April 17 to 19, 2015, and the second from June 5 to 7, 2015, both in Edmonton, Alberta.
From a sampling frame provided by the postal service covering northern Alberta, 3000 potential participants were randomly selected and sent information packages about the juries. The 224 package recipients who manifested a willingness to participate were screened by telephone interviews through which researchers collected demographic information. Health care workers, current patients, individuals involved in advocacy, and others with a preexisting interest in the health care system were excluded from the pool of potential participants. From those remaining, a sample stratified by age, ethnicity, socioeconomic status, and occupation was drawn, with random selection within groups (Table 1) .
Each jury started with the testimony of expert witnesses, whose role was to familiarize participants with issues relating to rare diseases, from various perspectives. Among the information provided to the group by the witnesses, decision makers from provincial bodies gave an overview of the system for approval and reimbursement of therapies in Alberta and of the current issues they were most concerned with at the time. A physician who treated patients with rare diseases gave general facts about rare disease patients in Alberta and the issues they face, and the options open to a clinician to obtain treatments that are not usually covered. A patient with rare disease and a mother and caregiver of such a patient both told their personal histories, which touched on some of the themes the clinician and decision makers had talked about. A representative of the pharmaceutical industry discussed the high costs and difficulties of doing research with a small number of patients, the need to apply to health authorities for coverage, and the influence of public payers on private manufacturers' investment decisions.
For the following day and a half, jurors were asked to complete a series of deliberative exercises.
For this exercise, each jury was divided into three groups, two with five members and one with six members. Each group was assisted by two researchers working as facilitators. First, the group was presented with a set of cards, each containing a health state profile described by five attributes, with each attribute having three possible levels ( Table 2 ). Profiles described real 
diseases, to ensure they were realistic, but participants were not told the names of the diseases represented by the profiles to minimize bias due to experiences with particular conditions. The group then ranked these diseases from most severe (1) to least severe (14 in the first jury, 15 in the second jury). It was important that jurors themselves ordered conditions by severity. Otherwise, a choice to treat a large population might indicate either that jurors prioritize the larger number or that they consider the condition of the larger number to be more severe. After diseases were ranked, facilitators presented a scenario in which the group had to choose between a large population (10,000 patients) and a small population (100 patients), both in the health state ranked as most severe: Which population would the group prioritize if only one could receive treatment? Participants were not told the expected health gains from treatment, to avoid either the assumption that the larger health gains would go to the largest number or that the larger health gains would go to those starting at the most severe baseline. If asked, facilitators said the expected gains were unknown.
The groups, as expected, selected the large population. Facilitators then posed the same question, iteratively, each time moving the large population one step up in the ranking of conditions and maintaining the small population at the most severe state. This process was repeated until participants "tipped," choosing to prioritize the small population in the most severe state over the large group in a less severe state. The groups' collective tipping point was considered to be the one where most chose to prioritize the small population. To capture minority views, the exercise continued until all participants had chosen to prioritize the small population.
Of the six groups that undertook the exercise, five were recorded and transcribed for thematic analysis. Transcripts were entered into NVivo software (QSR International, London). Coding started with a descriptive codebook, with categories corresponding to the attributes of health states ("life expectancy," "pain and discomfort," etc.). During the first round of coding, new codes were added corresponding to recurring themes (e.g., "hope," "alternative symptom relief," and "activities of daily living/independence"). Subsequent rounds of coding identified instances of these emerging themes throughout the data. This allowed prevalent perceptions of each attribute to be identified, as well as overarching themes that cut across attributes and therefore may reflect principles or values that consistently matter to jurors.
Results
All groups arrived at similar severity rankings of the disease profiles. Five of the six groups tipped from treating the large population to treating the small population at or near the midpoint of the severity spectrum. In the first jury's three groups, the tipping points were the conditions ranked at number 5, 6, and 7 in the 1 to 14 spectrum. In the second jury's three groups, the tipping points ranked at number 7, 7, and 3 in the 1 to 15 spectrum.
Groups' Views on Each Attribute
When deliberating about which conditions are more severe, jurors' main strategy was to compare the subjective experience of being in each condition, putting themselves "in the shoes" of the patients.
As might be expected given the focus on subjective experience, "pain and discomfort" was the most salient dimension in jurors' assessment of severity:
4: So pain and discomfort. That's-the main goal of medicine, or one of them, is to alleviate pain. 3: We want to prolong life, but not in pain. "Life expectancy" was in some cases valued as time for improving one's health state, and in other cases valued according to the quality of the life being lived (see the "Emphasis on the subjective experience of hope" section).
"Physical impairment" was associated with loss of independence and ability to carry out activities of daily living, and, consequently, loss of life enjoyment:
2: There's no happiness at all in that one. Severely impaired? That's like, just lying there. (Group 3)
There were conflicting views about what the subjective experience of "cognitive impairment" would be like. Some jurors thought that lacking awareness of one's situation might mitigate severity, but others thought the opposite:
3: But cognitive-severely [cognitively impaired] just means they can't remember, they can still maybe just be happy. They just don't remember. (Group 3) Table 2 -Attributes and levels of health states.
Jury
Attribute Level "Caregiver burden" was discussed not only in the second jury, when it was an attribute of the health states described in the cards, but also in the first jury, when it was introduced to the discussion by participants with no prompting. Jurors considered the impact of high caregiver burden on families, but did not seem to include it in the concept of severity. In keeping with the focus on the patients' experience, one theme that came up in connection with caregiver burden was the experience that the patient might have of feeling like a burden to others, especially in the context of severe physical impairment that leaves the patient in need of constant assistance for personal care and daily activities.
1: … But say you're severely [physically impaired] and you can't do nothing but only for one to five years. As opposed to somebody who's going through their day and now you're incapable of not doing some of your daily-you feel like you're a burden. And it's going to make your depression worse over time. It is treatable, and you have time, but. (Group 2)
Cross-Attribute Patterns in Ranking Severity

Discounting of symptoms that can be relieved without treating the illness
Jurors reduced the severity attributed to health states when there was a possibility of relieving symptoms, even if relieving the symptoms did not treat the disease or the condition itself. Instances of this pattern are described in this section.
In the handouts containing the descriptions of the attributes and levels of health states (see Supplemental Materials found at https://doi.org/10.1016/j.jval.2018.03.010), jurors were told that the mild and moderate levels of pain could be controlled with drugs, whereas severe pain could not. As a result, mild pain and moderate pain were treated interchangeably and not given much weight in attributing severity. This occurred in all groups. Jurors were not told whether depression and anxiety at any level could be relieved by drugs. Nevertheless, some groups made the reasonable assumption that psychiatric treatment could relieve this symptom, and therefore also discounted depression and anxiety when judging the severity of health states containing depression. One group saw caregiver burden as a "symptom" that could be relieved in ways other than by treating the disease. This group then decided to discount caregiver burden in the disease severity rankings for this reason.
5: … The caregiver thing is not unimportant, but they're … the caregiver has an opportunity or potential opportunity to relieve him or herself from that role for some period of time. Not always, but there is that potential …. (Group 5) Emphasis on the subjective experience of hope Appeals to hope were a recurring feature of the deliberations. Hope was characterized as a belief or subjective feeling that a person in the health state being discussed might experience, that however bad their experience is, it can get better in the future. The absence of subjective hope led jurors to rank a disease as more severe. Some instances of this pattern are described.
Depression, when understood in a way that emphasized hopelessness about the future, carried more weight than it did when the discussion emphasized the experience of low mood or lack of life enjoyment. The latter view of depression was given less weight in the attribution of severity than other attributes of the health states. Severe pain that cannot be relieved, besides being considered the worst attribute from an experiential point of view, was also viewed as a hopeless state to be in because of there being no perspective of relief.
2: Because this is worse, for me, myself. Like, I'd rather be in depression than … be in pain and not [able] to function, because you're in pain and you can't do anything about it. And that sucks rather than just not enjoying life enough. (Group 6) Longer life expectancy was considered to reduce severity, as would be expected, when it was understood as more time to potentially improve one's health state by receiving treatment or by new treatments becoming available. 
Trading Off Severity and Numbers
When deliberating about whether to prioritize a small and more severely ill population (100 patients) or a large and less severely ill population (10,000 patients), jurors began by choosing the larger number. This was expected, because in the first few questions the large and small populations were both in severe states of health. As the large number of patients was moved to less severe conditions, however, the presumption of priority to the larger population weakened. Jurors expressed a willingness to sacrifice numbers for the sake of prioritizing the worst off, to some extent.
5:
Well, obviously, if we continue going down this way, we're going to sacrifice 100 every time. 3: No, I think we might allow some people to live with some kind of thing and save these guys. 5: Just because the condition is so bad.
Subjective experience continued to be a primary consideration in trade-off discussions, and intractable pain continued to be the factor most prominently taken into account. Few participants chose the small population when the large population had intractable pain. Among all other participants, tipping toward prioritizing the small group began as soon as the large population no longer had extreme pain and would subsequently only be in health states containing treatable (mild or medium) pain.
Facilitator: At this point you would switch [to the smaller population], and why is that? Why would you switch at this point? 2: Because these people are severely impaired at this point. And the pain and discomfort is extreme. At this point I'm assuming that with mild pain and discomfort [for the larger population], it could be controlled. (Group 4) After the first participants began tipping, there were explicit disagreements about whether two conditions were different enough in severity to justify leaving the large population untreated:
2: I would argue because those life expectancies [of the large population, 1 to 5 years; and the small population, less than 1 year] are fairly close, like less than a year could be 11 months, and 1 to 5 years can be 1 year. So like, if it was over 5 years then I will be more lenient, like 1 to 5 years can be fairly close together. … I think it comes out to the quantity of people again. 
Discussion
When a health state combined longer life expectancy with intractable pain, groups viewed the condition as extremely undesirable and therefore severe-even more severe than a health state containing extreme pain and shorter life expectancy. This explains decisions that could be thought of as wrong or irrational: three of the six groups picked as the most severe condition a health profile that strictly dominates another profile, which the group ranked as less severe. These choices do not appear to be mistakes on the part of the jurors. There is no evidence of misunderstanding of the health states or of the ranking task in the transcripts. Rather, these choices appear to indicate that the concept of severity used by the groups refers only to current quality of life and does not include life expectancy.
The idea that a longer life expectancy with very low quality of life may be bad for the patient was present at the ranking stage but not at the priority setting stage. This appears to be because when there is a possibility of treatment, longer life is no longer a "sentence" to poor quality of life. Therefore, both patient populations could be assumed to want to receive treatment, and those with less time to live if untreated have the most pressing need. In other words, shorter life expectancy, which in the first stage is sometimes counted as a reason to rank a condition as less severe than an otherwise similar condition with a longer life expectancy, now counts in favor of giving it more priority. Jurors' understanding of severity as excluding life expectancy, therefore, is an interesting observation but has no implications for jurors' priority setting choices.
Intractable pain stood out as a particularly strong motivator for tipping, or choosing to prioritize a population of 100 patients over a population of 10,000 patients. Four of the six groups ranked the four profiles containing extreme pain (that cannot be relieved with medication) as the four most severe. This was to be expected, given the correlations between dimensions of disease profiles (i.e., more pain tracks more physical impairment and higher caregiver burden). Nevertheless, pain was usually the dimension that was mentioned as justification for prioritizing the small population. Strong disagreement over whether to "tip" toward the small population usually started when the large population no longer had extreme pain, whereas the small population, remaining constant at the most severe condition, did.
The values expressed by the participants have the following implications that are relevant to the problem of rare diseases (all else being equal):
1. Lack of alternative treatments or options to manage symptoms, particularly pain, takes priority over large numbers. 2. Urgency takes priority over large numbers if the life-extending intervention can offer hope of an acceptable quality of life in the future (e.g., because of new treatments becoming available). 3. Patients' needs take priority over those of caregivers. 4. The consideration of whether a treatment is disease-altering rather than symptom management takes low priority.
Study Limitations
Sampling was geographically limited to northern Alberta, but previous research has shown high consistency between outcomes of citizens' juries in northern and southern Alberta [19] .
A limitation of the analysis is that it was performed by a single coder, and therefore was vulnerable to observer bias. This was mitigated by keeping the coding as close as possible to the transcripts, using participants' own words as codes whenever possible. To minimize the scope for projection or introduction of idiosyncratic views [22] , reasons for participant's choices were not imputed unless they were stated explicitly, as demonstrated by the illustrative quotes provided. Possible framing effects may have affected the results. Although the format of the exercise framed both options in each trade-off question in the same terms, giving the small and the large populations equal salience, it is possible that hearing from a patient with a rare disease and from the mother of such a patient V A L U E I N H E A L T H 2 1 ( 2 0 1 8 ) 5 3 2 -5 3 7 the day before the exercise made the plight of those affected by rare diseases more vivid to participants, disposing them toward the smaller population. The framing of the jury as an activity relating to rare diseases may also have had this effect. Nevertheless, such effects, if any, appear to have been small: caregiver burden was not prioritized, in spite of the testimony of the mother of a patient with a rare disease also having the potential of making the plight of caregivers more salient.
Because of the narrow scope of this study, which looks only at severity of initial health state and number of patients, holding all else equal, these findings alone do not predict or guide real-world judgments about treatments. As frameworks of broader scope [14] and other citizens' juries carried out in Alberta [23, 24] show, severity and numbers are relevant to resource allocation, but other factors can be equally or more important. Most notably, this study did not take into account potential health gains or costs of treatment. The abstract framing of the diseases and the questions also leaves out concrete and contextual information that would affect real-world priority setting choices.
Conclusions
The findings of the study indicate that, all else being equal, the public would support giving priority to a smaller but more severely ill patient population over a larger patient population when prioritizing the needs of the few is life-saving, extends life enough to give hope of future improvement, and relieves otherwise intractable symptoms, especially pain.
